Tuspetinib

• CAT Number: I045191
• CAS Number: 2294874-49-8
• Molecular Formula: C29H33ClN6
• Molecular Weight: 501.07
• Purity: ≥95%
• Synonyms: 5-chloro-N-[3-cyclopropyl-5-[[(3S,5R)-3,5-dimethylpiperazin-1-yl]methyl]phenyl]-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine
• IUPAC Name: 5-chloro-N-[3-cyclopropyl-5-[[(3R,5S)-3,5-dimethylpiperazin-1-yl]methyl]phenyl]-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine
• InChI: InChI=1S/C29H33ClN6/c1-17-4-7-24-25(12-31-27(24)8-17)28-26(30)13-32-29(35-28)34-23-10-20(9-22(11-23)21-5-6-21)16-36-14-18(2)33-19(3)15-36/h4,7-13,18-19,21,31,33H,5-6,14-16H2,1-3H3,(H,32,34,35)/t18-,19+
• InChIKey: FZLSDZZNPXXBBB-KDURUIRLSA-N
• SMILES: C[C@@H]1CN(C[C@@H](N1)C)CC2=CC(=CC(=C2)NC3=NC=C(C(=N3)C4=CNC5=C4C=CC(=C5)C)Cl)C6CC6

Tuspetinib（Cat No.:I045191）is an orally bioavailable, potent multi-kinase inhibitor targeting FLT3, SYK, JAK, and other kinases implicated in hematologic malignancies. It is designed to overcome resistance mutations in FLT3, including ITD and TKD variants, while also modulating additional signaling pathways that promote leukemia cell survival and proliferation. Tuspetinib has shown strong preclinical and early clinical activity in acute myeloid leukemia (AML), including in patients resistant to prior FLT3 inhibitors. Its broad yet selective kinase inhibition profile makes it a promising therapeutic candidate for difficult-to-treat blood cancers with complex mutational landscapes.